Mark R Young, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1504 N 1st St, Indianola, IA 50125 Phone: 515-961-3700 Fax: 515-962-0160 |
News Archive
Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.
A detailed report, available on the preprint server medRxiv*, describes the various facets of the second wave that set it apart from the first. The report also contains the findings of an extended SIR model that explored the potential effects of intervention at various time points in the second wave.
The study compared the radiation dose to patient's skin during transcatheter arterial embolization, a procedure that blocks the flow of a blood to a tumor. Doses were assessed for 12 patients using a new angiography unit with a digital flat-panel system and 12 using a conventional unit for angiographic imaging.
Coffee, that morning elixir, may give us an early jump-start to the day, but numerous studies have shown that it also may be protective against type 2 diabetes. Yet no one has really understood why.
› Verified 6 days ago